| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | CLO, Interim CFO, Corp Sec. | Common Stock | 2.4K | $9.05K | $3.77 | May 24, 2023 | Direct |
| Aceragen, Inc. | SVP AND GENERAL COUNSEL | Stock Options (Right to Buy) | 25.4K | Jan 20, 2023 | Direct | ||
| Prelude Therapeutics Inc | CLO, Interim CFO, Corp Sec. | Employee Stock Option (Right to Buy) | 25K | May 14, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | May 14, 2024 | 1 | $0 | 4 | May 16, 2024 | CLO, Interim CFO, Corp Sec. |
| PRLD | Prelude Therapeutics Inc | Mar 1, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Chief Legal Officer, Corp Sec. |
| PRLD | Prelude Therapeutics Inc | May 24, 2023 | 1 | $12.9K | 4 | May 25, 2023 | Chief Legal Officer, Corp Sec. |
| PRLD | Prelude Therapeutics Inc | Mar 1, 2023 | 1 | $0 | 4 | Mar 2, 2023 | Chief Legal Officer, Corp Sec. |
| PRLD | Prelude Therapeutics Inc | Feb 20, 2023 | 0 | $0 | 3 | Feb 22, 2023 | Chief Legal Counsel, Corp Sec. |
| ACGN | Aceragen, Inc. | Jan 20, 2023 | 1 | $0 | 4 | Feb 2, 2023 | SVP AND GENERAL COUNSEL |
| IDRA | IDERA PHARMACEUTICALS, INC. | Jan 6, 2023 | 2 | -$85.2K | 4 | Jan 10, 2023 | SVP AND GENERAL COUNSEL |
| IDRA | IDERA PHARMACEUTICALS, INC. | Jul 6, 2022 | 1 | $0 | 4 | Jul 7, 2022 | SVP AND GENERAL COUNSEL |
| IDRA | IDERA PHARMACEUTICALS, INC. | Apr 1, 2022 | 1 | $0 | 4 | Apr 4, 2022 | SVP AND GENERAL COUNSEL |
| IDRA | IDERA PHARMACEUTICALS, INC. | Jan 24, 2022 | 1 | $0 | 4 | Jan 26, 2022 | SVP AND GENERAL COUNSEL |
| IDRA | IDERA PHARMACEUTICALS, INC. | Jul 8, 2021 | 1 | $0 | 4 | Jul 12, 2021 | SVP AND GENERAL COUNSEL |